Prognosis Grim for Zetia and Vytorin
MedHeadlines - Clogged arteries. Plaque build-up. Cholesterol. Heart attack. Stroke. Zetia. Vytorin. Crestor. Zocor. Lipitor. So many scary sounding words. And they all mean important decisions need to be made. What’s a person to do? The first thing to do, of course, is to see a doctor. Chances are, he or she will prescribe one of the very popular, and very well advertised, drugs listed above to treat the symptoms and medical conditions also mentioned above. But are they the best drugs for the situation?
On Monday, two major drug companies announced the disappointing results of a joint study they’ve recently concluded on the drug Vytorin, which both companies, Merck and Schering-Plough Pharmaceuticals, market extensively. Vytorin is a combination of two other popular cholesterol-lowering drugs, Zocor and Zetia.
The disappointment comes from study results that indicate no significant benefit to plaque-laden arteries when taking the prescription medication as a means of lowering cholesterol levels in the bloodstream. In addition to controlling cholesterol, the drug was also expected to stop, or at least slow, the build-up of plaque along artery walls and to reduce the thickness of the plaque already there in study subjects who took the drug throughout the two-year study.
Vytorin, and Zetia as a result of its association to Vytorin, produced no significant improvement on plaque build-up although they are both effective in reducing cholesterol levels. In some patients receiving Vytorin during the study, arterial plaque actually increased. The other popular cholesterol-lowering drugs - Crestor, Lipitor, and Zocor - not only reduce cholesterol levels effectively but they also generate significant reduction in arterial plaque deposits.
Based on prescriptions written in 2006, Zetia was prescribed 14 million times and Vytorin 18 million times, making them two of the most commonly used cholesterol-lowering drugs on today’s market.
Upon learning of the announcement, some doctors suggested the drugs should no longer be considered a first line of defense against elevated cholesterol levels and should be prescribed instead only when other, more effective, drugs have failed. They further claim that by taking these medications, patients risk higher levels of heart disease and side effects while being denied access to safer, more effective, medications instead.
Stock prices dropped markedly for both drug companies after the study results were announced. Schering earns about 70% of its income from the sale of Vytorin and Zetia. Merck has been trying to improve its tarnished reputation after its painkiller, Vioxx, was removed from the market a few years ago due to dangerous side effects.
- Mesothelioma Treatment Reaches a New Breakthrough Moment
- Jeez, Doc, Get Some Sleep!
- Medical Exam Predicts Type 2 Diabetes as Well as Genetic Testing
- Medicaid Pays Millions for Unapproved Drugs
- Where’s the Beef? All Fast Foods Based on Corn
- Is Financial Fraud Behind Dramatic Spike in Pediatric Antipsychotics?
- Will Fast-Food Ads Follow the Marlboro Man Into History?
Loading ...
Should a person continue to take Vytorin?
We can remember those of 9/11/01 but can’t help them.
We CAN help those 300-500 that die each day from adverse effects of prescription drugs and the 300+ that are hospitalized from the same. If you wish to debate this, you will surely lose.
The drugs don’t cure degeneratie disease, but treat “surrogate end points” (i.e. tumor reduction, sugar levels), while the underlying cause is neglected and the REAL health status CONTINUES TO WORSEN. The BEST of integrative and alternative medicine addresses the cause and often effects a reversal or cure.
If you wish to debate this also, you have no chance, regardless of who you are.
Want some good reading material? Get “Deadly Medicine” at Amazon (for $1 or less).
G. Templin